An affiliate of the American Society of Clinical Oncology - Learn More

Open Trials

Breast Cancer Trials:

HER Negative ER/PR positive for locally advanced or metastatic. Requires previous treatment with taxane in Neo adjuvant or adjuvant, but not metastatic setting. Any number of previous hormonal therapies are allowed.

Phase 3 trial with Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, MBC (CONTESSA)

https://clinicaltrials.gov/ct2/show/NCT03326674?term=odonate&rank=1

For questions, please contact 480-398-7671.

Previously treated metastatic HER2+Breast Cancer

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA).  New sub-study includes margetuximab plus chemotherapy with decreased infusion time.
https://clinicaltrials.gov/ct2/show/NCT02492711?term=CP-MGAH22-04&rank=1
For questions, please contact 480-398-7671.

Colorectal Cancer Trials:

2nd line treatment for Metastatic Colorectal Cancer

Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab.

https://clinicaltrials.gov/ct2/show/NCT03368859?term=m14-064&rank=1

For questions, please contact 480-398-7671

 

Lung Cancer Trials:

2nd or 3rd line treatment for Non-Small Cell Lung Cancer (NSCLC) after prior Platinum-Based Chemotherapy

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)
https://clinicaltrials.gov/ct2/show/NCT02504489
For questions please contact 480-398-7671.

Device study for NSCLC Stage 4 after Platinum Failure

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (LUNAR). https://clinicaltrials.gov/ct2/show/NCT02973789?term=ef-24&rank=1
For questions, please contact 480-398-7671

Lymphoma Trials:

Previously treated Non-Hodgkin’s Lymphoma (Follicular, Small Lymphocytic Leukemia, Marginal Zone, Diffuse Large B-Cell Lymphoma)

https://clinicaltrials.gov/ct2/show/NCT02793583?term=UTX-TGR-205&rank=1
For questions please contact 480-398-7671.

 

Melanoma Trials:

Maintenance Treatment for Patients with Resected Stage IIB, IIC, or III Melanoma

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence.
https://clinicaltrials.gov/ct2/show/NCT01546571?term=103A-301&rank=1
For questions, please contact 480-398-7671.
*ENROLLMENT IS CURRENTLY ON HOLD FOR THIS TRIAL**

 

Prostate Cancer Trials:

Metastatic castration-resistant prostate cancer with no prior treatment

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)
https://clinicaltrials.gov/ct2/show/NCT03072238?term=CO39303&rank=1
For questions please contact 480-398-7671.

 

Registry Trials:

Observational study involving Guardant360® Use and Outcomes In People With Advanced Cancer (GEODE).

Currently enrolling NSCLC patients that have had the Guardant360 test ordered within 8wks. This is to discover how the results from the Guardant360 test affect clinical decisions and the outcomes associated with therapies selected for patients whose tumors have specific genetic mutations.

https://clinicaltrials.gov/ct2/show/NCT03477474?term=geode&rank=3

For questions, please contact 480-398-7671.